Objective: To investigate the therapeutic effect of Yiqi Fumai oral liquid on patients with coronary heart disease complicated with chronic heart failure. Methods: 80 patients with coronary heart disease combined with chronic heart failure admitted to our hospital from January 2023 to January 2024 were selected as the study objects. The patients were divided into control group and observation group by random number table method, with 40 cases in each group. The control group was treated with conventional western medicine. The observation group was treated with Yiqi Fumai oral liquid combined with conventional western medicine. Both groups were treated for 2 weeks. The clinical efficacy, serum factors [N-terminal brain natriuretic peptide precursor (NT-proBNP), hypersensitive C-reactive protein (hs-CRP)] levels, cardiac function indicators [left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF)] and adverse reactions of the two groups were analyzed and compared. Results: The total effective rate of observation group was significantly higher than that of control group (P < 0.05). After treatment, the levels of serum NT-proBNP and hs-CRP in both groups were significantly lower than before treatment, and the levels of serum NT-proBNP and hs-CRP in the observation group were significantly lower than those in the control group after treatment (P < 0.05). After treatment, LVEF in both groups was significantly higher than before treatment, LVESD and LVEDD were significantly lower than before treatment, and the improvement of various cardiac function indexes in the observation group was significantly greater than that in the control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion The combination treatment of Yiqi Fumai oral liquid can improve the therapeutic effect, reduce the level of NT-proBNP, inhibit inflammation and improve heart function in patients with CHD complicated with chronic heart failure with high safety.